Advertisement

New Optical Improvements in Bladder Cancer Diagnosis: Seeing Better for a Better Management?

  • Benjamin Pradère
  • Idir Ouzaid
  • Evanguelos Xylinas
Chapter

Abstract

New imaging techniques in bladder cancer can be classified according to their aim as macroscopic and microscopic. Macroscopic techniques include photodynamic diagnosis (PDD) and narrow-band imaging (NBI) while microscopic techniques include optical coherence tomography (OCT) and confocal laser endomicroscopy (CLE). PDD is able to reduce the risk of recurrence but no data, to date, have demonstrated its association with a reduction in disease progression. Cost analyses for using PDD suggest that its use can reduce the overall cost of bladder cancer care by improving the patients’ recurrence-free survival. Microscopic technologies are currently in the early stages of experimental research but, in the future, could provide real-time evaluation and thereby bring the microscope into the office cystoscopy and in the operative room, with great improvements in bladder cancer diagnosis and management.

Keywords

PDD NBI SPIES OCT CLE New technologies 

References

  1. 1.
    Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the european union. Eur Urol. 2016;69(3):438–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–61.PubMedCrossRefGoogle Scholar
  3. 3.
    Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SF, Stenzl A, Stepp H, Zaak D, Witjes JA. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624–38.PubMedCrossRefGoogle Scholar
  4. 4.
    Collaud S, Juzeniene A, Moan J, Lange N. On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anticancer Agents. 2004;4(3):301–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 2008;53(6):1138–48.PubMedCrossRefGoogle Scholar
  6. 6.
    Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, Ray E, Fradet Y, Karl A, Burgues JP, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, Muschter R, Popken G, Konig F, Knuchel R, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174(3):862–6. discussion 866.PubMedCrossRefGoogle Scholar
  8. 8.
    Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M, Hexvix PCBSG. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004;171(1):135–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, Droller MJ, Group PBS. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178(1):68–73. discussion 73.PubMedCrossRefGoogle Scholar
  10. 10.
    Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, Filbeck T. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007;69(4):675–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Burger M, Stief CG, Zaak D, Stenzl A, Wieland WF, Jocham D, Otto W, Denzinger S. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology. 2009;74(6):1282–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol. 2002;168(1):67–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005;96(6):798–802.PubMedCrossRefGoogle Scholar
  14. 14.
    Burger M, Zaak D, Stief CG, Filbeck T, Wieland WF, Roessler W, Denzinger S. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol. 2007;52(1):142–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Denzinger S, Wieland WF, Otto W, Filbeck T, Knuechel R, Burger M. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int. 2008;101(5):566–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Schumacher MC, Holmang S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol. 2010;57(2):293–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Kriegmair M, Karl A, Shen Y, Grossman HB. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1907–13.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Stenzl A, Penkoff H, Dajc-Sommerer E, Zumbraegel A, Hoeltl L, Scholz M, Riedl C, Bugelnig J, Hobisch A, Burger M, et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer. 2011;117(5):938–47.PubMedCrossRefGoogle Scholar
  19. 19.
    Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, Soloway MS, Karl A, Burger M. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol. 2012;188(1):58–62.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S, Stenzl A. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295–300.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int. 2012;110(11 Pt B):E680–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Bryan RT, Billingham LJ, Wallace DM. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int. 2008;101(6):702–5. discussion 705–706.PubMedCrossRefGoogle Scholar
  23. 23.
    Geavlete B, Multescu R, Georgescu D, Stanescu F, Jecu M, Geavlete P. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumors--results of a prospective, randomized comparison to the standard approach. Urology. 2012;79(4):846–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Goh AC, Tresser NJ, Shen SS, Lerner SP. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology. 2008;72(1):133–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Crow P, Uff JS, Farmer JA, Wright MP, Stone N. The use of Raman spectroscopy to identify and characterize transitional cell carcinoma in vitro. BJU Int. 2004;93(9):1232–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Jain M, Robinson BD, Scherr DS, Sterling J, Lee MM, Wysock J, Rubin MA, Maxfield FR, Zipfel WR, Webb WW, et al. Multiphoton microscopy in the evaluation of human bladder biopsies. Arch Pathol Lab Med. 2012;136(5):517–26.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Schafauer C, Ettori D, Roupret M, Phe V, Tualle JM, Tinet E, Avrillier S, Egrot C, Traxer O, Cussenot O. Detection of bladder urothelial carcinoma using in vivo noncontact, ultraviolet excited autofluorescence measurements converted into simple color coded images: a feasibility study. J Urol. 2013;190(1):271–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Benjamin Pradère
    • 1
  • Idir Ouzaid
    • 2
  • Evanguelos Xylinas
    • 2
  1. 1.Department of UrologyUniversity of ToursToursFrance
  2. 2.Department of UrologyBichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris Descartes UniversityParisFrance

Personalised recommendations